APGE

Apogee Therapeutics Inc

132.73

Jun 30 • 04:00PM ET +0.12 (0.09%)

Healthcare Biotechnology USA Mid NASD

Peers: KYMR BMRN MDGL RYTM VKTX KRYS NUVL AXSM INCY NBIX

| Held by: XBI IWM VTI TCAF IWO IBB VXF SCHA VTWO ITOT

Scroll to Statements

Index	RUT
Market Cap	9.98B
Enterprise Value	8.93B
Income	-274.62M
Sales	0.00M
Book/sh	16.77
Cash/sh	14.10
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	261
IPO	Jul 14, 2023

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	7.91
P/C	9.42
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	32.59
Current Ratio	32.59
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-4.33
EPS next Y	-5.54
EPS next Q	-1.07
EPS this Y	-5.26%
EPS next Y	-24.72%
EPS next 5Y	-12.96%
EPS past 3/5Y	-75.11% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-22.17%
Sales Y/Y TTM	-
EPS Q/Q	-11.87%
Sales Q/Q	-
Earnings	May 11 BMO
EPS/Sales Surpr.	0.83% -

Insider Own	24.30%
Insider Trans	-10.06%
Inst Own	92.96%
Inst Trans	17.12%
ROA	-27.35%
ROE	-28.47%
ROIC	-21.78%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	29.61%
SMA50	45.96%
SMA200	82.58%
Trades

Shs Outstand	61.40M
Shs Float	56.91M
Short Float	18.41%
Short Ratio	4.48
Short Interest	10.48M
52W High	133.16 -0.32%
52W Low	34.34 286.52%
Volatility	0.21% 4.13%
ATR (14)	4.89
RSI (14)	81.26
Beta	0.32
Rel Volume	2.38
Avg Volume	2.34M
Volume	5,436,413

Perf Week	-0.11%
Perf Month	61.59%
Perf Quarter	68.61%
Perf Half Y	71.66%
Perf YTD	75.85%
Perf Year	205.62%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	2.60
Target Price	132.79
Prev Close	132.61
Price	132.73
Change	0.09%

Date	Action	Analyst	Rating Change	Price Target Change
May-01-26	Initiated	Rothschild & Co Redburn	Buy	$140
Mar-18-26	Initiated	Truist	Hold	$83
Jan-22-26	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$83
Jan-07-26	Initiated	Wolfe Research	Peer Perform
Dec-17-25	Initiated	Stephens	Overweight	$95
Dec-10-25	Initiated	Deutsche Bank	Buy	$103
Nov-03-25	Initiated	Craig Hallum	Buy	$109
Oct-21-25	Initiated	Mizuho	Outperform	$105
Sep-25-25	Initiated	RBC Capital Mkts	Outperform	$60
Jul-07-25	Reiterated	BTIG Research	Buy	$100 → $115
Mar-13-25	Initiated	Citigroup	Buy	$95
Nov-25-24	Initiated	Canaccord Genuity	Buy	$89
May-10-24	Initiated	BofA Securities	Buy	$80
Dec-20-23	Initiated	BTIG Research	Buy	$43
Aug-08-23	Initiated	Wedbush	Outperform	$40
Aug-08-23	Initiated	TD Cowen	Outperform
Aug-08-23	Initiated	Stifel	Buy	$34
Aug-08-23	Initiated	Jefferies	Buy	$29
Aug-08-23	Initiated	Guggenheim	Buy	$29

Show Previous Ratings

Jun-26-26 02:39PM	Healthcare stocks have become a haven for investors ditching tech (MarketWatch)
Jun-25-26 01:53PM	Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders? (PR Newswire)
Jun-22-26 11:04PM	Why Did INTC, KEEL, APGE Stocks Hit 52-Week Highs Today? (Stocktwits) +46.66%
04:20PM	Are ACA, CZR, APGE Obtaining Fair Deals for their Shareholders? (PR Newswire)
04:08PM	AbbVie Goes On The Offensive With $10.9 Billion Takeover (Investor's Business Daily)
02:59PM	Loading…
02:59PM	AbbVie's $10.9 Billion Apogee Deal Joins a $200 Billion Pharma Spree (GuruFocus.com)
11:33AM	AbbVie deepens immunology legacy in $10.9bn Apogee buyout (Pharmaceutical Technology)
11:12AM	AbbVie's Deal with Apogee; Regenxbio Moves on Gene Therapy Drug \| Stock Movers (Bloomberg)
10:04AM	AbbVie to acquire Apogee Therapeutics in $10.9B deal (Proactive)
09:08AM	Apogee Therapeutics, BitFuFu rise premarket; AbbVie gains after deal (Investing.com)
09:08AM	Why AbbVie Is Spending $11 Billion to Buy Apogee Therapeutics (Barrons.com)
08:58AM	AbbVie Strikes $10.9 Billion Deal for Apogee to Strengthen Future Immunology Portfolio (ABBV) (InvestorsHub)
08:32AM	AbbVie acquires Apogee Therapeutics for $10.9 billion (Quartz)
07:42AM	AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash (The Wall Street Journal)
07:06AM	Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion. (Barrons.com)
07:00AM	Loading…
07:00AM	AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio (PR Newswire)
Jun-20-26 12:11PM	AbbVie would gain an experimental eczema drug by buying biotech: report (MarketWatch)
Jun-19-26 04:09PM	Stocks Stall as Iran Nuclear Talks Hit Early Snag: Markets Wrap (Bloomberg)
May-28-26 04:01PM	Apogee Therapeutics to Participate in Upcoming June Conferences (GlobeNewswire) +5.55%
02:43PM	Apogee Therapeutics lines up $1.3B strategic financing for zumilokibart program (Proactive)
May-27-26 04:06PM	Why Apogee Slipped On Its Dupixent-Rivaling Eczema Results (Investor's Business Daily) -6.11%
02:33PM	Blackstone Backs Apogee With Up To $1.3 Billion (GuruFocus.com)
08:06AM	Apogee Therapeutics Shares Surge Following $1.3 Billion Blackstone Financing Partnership (APOG) (InvestorsHub)
06:31AM	Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart (GlobeNewswire)
06:30AM	Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis (GlobeNewswire)
May-26-26 04:01PM	Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026 (GlobeNewswire)
May-11-26 07:00AM	Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results (GlobeNewswire)
Mar-26-26 04:01PM	Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million (GlobeNewswire)
Mar-24-26 09:53PM	Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering (GlobeNewswire) -7.87% +7.58%
Mar-23-26 04:01PM	Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering (GlobeNewswire) +19.99%
10:01AM	Loading…
10:01AM	How Apogee, Up 14%, Plans To Take On Rival Regeneron's Eczema Drug (Investor's Business Daily)
08:15AM	Apogee strengthens case for longer-lasting eczema drug (BioPharma Dive)
06:30AM	Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis (GlobeNewswire)
Mar-22-26 07:51PM	Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026 (GlobeNewswire)
Mar-18-26 09:34AM	Block upgraded, Starbucks downgraded: Wall Street's top analyst calls (The Fly)
Mar-10-26 08:04AM	Wedbush Raises Price Target on Apogee Therapeutics (APGE) (Insider Monkey)
Mar-04-26 06:34AM	Apogee Therapeutics Teases 52-Week Zumi Durability Data, Phase III Path at TD Cowen Conference (MarketBeat) +5.56%
Mar-02-26 07:00AM	Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results (GlobeNewswire)
Feb-24-26 07:30AM	Apogee Therapeutics to Participate in Upcoming March Conferences (GlobeNewswire)
Feb-18-26 07:39PM	End of Apogee (APGE) Drug Collaboration Leads to Revised Analyst Expectations (Insider Monkey)
Feb-16-26 12:23PM	Here is Why Apogee Therapeutics (APGE) Appears Attractive (Insider Monkey)
Feb-12-26 09:07PM	Apogee Therapeutics touts quarterly-to-biannual AD dosing shift, expands asthma ambitions at conference (MarketBeat) +5.32%
Feb-05-26 08:00AM	Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-30-26 07:39PM	Elastic NV, Acadia Healthcare, and More Stocks See Action From Activist Investors (Barrons.com) -6.39%
Jan-12-26 12:00PM	Funding for Risky Biotechs Is Returning (The Wall Street Journal)
Jan-07-26 09:41AM	Wayfair upgraded, Instacart initiated: Wall Street's top analyst calls (The Fly)
Jan-06-26 06:00AM	Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook (GlobeNewswire)
Jan-05-26 04:01PM	Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026 (GlobeNewswire)
Dec-09-25 12:19AM	Strong Pipeline and Analyst Confidence Push Apogee Therapeutics Inc. (APGE) Toward Growth (Insider Monkey)
Nov-11-25 09:40AM	Is Apogee Therapeutics Inc. (APGE) Outperforming Other Medical Stocks This Year? (Zacks) +10.89%
Nov-10-25 07:10AM	Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
07:00AM	Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody (GlobeNewswire)
Nov-03-25 07:30AM	Apogee Therapeutics to Participate in Upcoming Conferences (GlobeNewswire)
Oct-30-25 09:55AM	Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 69.3%: Here's is How to Trade (Zacks)
Oct-17-25 09:55PM	BTIG Maintains a Buy on Apogee Therapeutics (APGE) (Insider Monkey)
Oct-14-25 09:55AM	Does Apogee Therapeutics Inc. (APGE) Have the Potential to Rally 72.52% as Wall Street Analysts Expect? (Zacks)
Oct-10-25 04:01PM	Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million (GlobeNewswire)
Oct-09-25 05:26PM	Why Apogee Therapeutics Stock Triumphed on Thursday (Motley Fool) +12.64%
01:08PM	Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out (Investor's Business Daily)
Oct-08-25 09:52PM	Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering (GlobeNewswire) +18.90%
04:01PM	Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering (GlobeNewswire)
Sep-30-25 04:00AM	RBC Capital Initiates Coverage of Apogee Therapeutics (APGE) With an Outperform Rating (Insider Monkey)
Sep-15-25 09:09AM	BofA Raises Apogee Therapeutics (APGE) PT to $87 Following Positive Phase 2 APEX Trial Results for Atopic Dermatitis (Insider Monkey)
Sep-11-25 07:30AM	Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress (GlobeNewswire)
Sep-03-25 07:30AM	Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum (GlobeNewswire)
Aug-11-25 07:00AM	Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-06-25 09:55AM	Wall Street Analysts See a 152.41% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High? (Zacks) -5.24%
Jul-31-25 11:38AM	Apogee Therapeutics, Inc. (APGE) Soars on Promising Phase 2 Results for Atopic Dermatitis Drug (Insider Monkey)
Jul-16-25 09:38AM	BTIG Raises PT on Apogee Therapeutics (APGE) to $115 From $100, Keeps a Buy Rating (Insider Monkey)
Jul-14-25 07:52AM	Canaccord Genuity Reiterated a Buy Rating on Apogee Therapeutics (APGE) (Insider Monkey)
Jul-08-25 03:31PM	Regeneron's Blockbuster Dupixent Faces a New Rival (Barrons.com) -7.21%
02:26PM	Apogee Therapeutics (APGE) Falls 17%, Positive Trial Results Fail to Impress Investors (Insider Monkey)
Jul-07-25 04:27PM	Apogee Dives. But It Could Eventually Rival Sanofi's Biggest Moneymaker. (Investor's Business Daily) -17.32%
10:09AM	Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot (Investor's Business Daily)
06:00AM	Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis (GlobeNewswire)
Jul-06-25 06:00PM	Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025 (GlobeNewswire)
04:01AM	Apogee Therapeutics Shares Positive Interim Phase 1b Results for APG808 in Asthma (Insider Monkey)
Jun-09-25 09:55AM	Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High? (Zacks)
May-29-25 07:30AM	Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-21-25 09:55AM	Wall Street Analysts Think Apogee Therapeutics Inc. (APGE) Could Surge 132.72%: Read This Before Placing a Bet (Zacks)
May-12-25 02:21PM	Why Is Apogee Therapeutics Stock Trading Higher On Monday? (Benzinga) +6.14%
06:05AM	Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results (GlobeNewswire)
06:00AM	Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody, in Patients with Mild-to-Moderate Asthma (GlobeNewswire)
06:00AM	Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4R Antibody, in Patients with Mild-to-Moderate Asthma (GlobeNewswire)
May-05-25 09:55AM	Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 134%: Here's is How to Trade (Zacks)
May-01-25 08:00AM	Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference (GlobeNewswire)
Apr-14-25 08:04AM	Apogee Therapeutics: Engineering Biologic Dominance (Seeking Alpha)
Mar-26-25 05:50PM	Is Apogee Therapeutics (APGE) Among the Best IPO Stocks to Buy in 2025? (InsiderMonkey)
Mar-03-25 12:16PM	Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial (Benzinga)
06:05AM	Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results (GlobeNewswire)
06:00AM	Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990) (GlobeNewswire)
Mar-01-25 09:22AM	Is Apogee Therapeutics, Inc. (APGE) the Best Small-Cap Stock to Buy Now? (Insider Monkey)
Feb-28-25 04:00PM	Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025 (GlobeNewswire)
Feb-25-25 07:30AM	Apogee Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-03-25 07:00AM	Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis (GlobeNewswire)
Jan-30-25 03:44PM	Heres Why Apogee Therapeutics, Inc. (APGE) Will Double in 2025 (Insider Monkey) +5.41%
Jan-29-25 07:30AM	Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Dec-10-24 07:00AM	Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions (GlobeNewswire)
Dec-03-24 06:52AM	Apogee Therapeutics Advances in I&I Disease Treatments (TipRanks)
Dec-02-24 06:00AM	Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day (GlobeNewswire)

Apogee Therapeutics, Inc. is a clinical stage biotechnology company. It offers treatment of atopic dermatitis (AD), ashma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded by Andrew Gottesdiener and Nimish P. Shah in 2022 and is headquartered in Waltham, MA.

Chief Financial OfficerMs. Jane Pritchett V. Henderson

Chief Medical OfficerDr. Carl Linden Dambkowski M.D.

Vice President of Investor RelationsMs. Noel Kurdi

Chief Legal Officer & Corporate SecretaryMr. Matthew Batters J.D.

Chief Development OfficerDr. Rebecca Dabora Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dambkowski Carl	Chief Medical Officer	Jun 22 '26	Sale	132.60	26,400	3,500,640	179,248	Jun 24 08:01 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Jun 22 '26	Sale	132.54	80,000	10,603,200	1,015,987	Jun 24 08:00 PM
CARL DAMBKOWSKI	Officer	Jun 22 '26	Proposed Sale	90.38	15,400	1,391,852		Jun 22 04:48 PM
HENDERSON MICHAEL THOMAS	Officer	Jun 22 '26	Proposed Sale	132.54	80,000	10,603,532		Jun 22 10:40 AM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Jun 10 '26	Sale	83.38	20,000	1,667,622	1,095,987	Jun 12 05:05 PM
Dambkowski Carl	Chief Medical Officer	Jun 03 '26	Option Exercise	22.86	4,125	94,298	211,148	Jun 05 08:00 PM
Dambkowski Carl	Chief Medical Officer	Jun 03 '26	Sale	78.71	5,500	432,905	205,648	Jun 05 08:00 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	May 13 '26	Sale	82.09	20,000	1,641,711	1,115,987	May 15 08:00 PM
HENDERSON MICHAEL THOMAS	Officer	May 13 '26	Proposed Sale	82.47	60,000	4,948,200		May 13 10:34 AM
Dambkowski Carl	Chief Medical Officer	May 06 '26	Option Exercise	22.86	4,125	94,298	212,523	May 08 08:00 PM
Dambkowski Carl	Chief Medical Officer	May 06 '26	Sale	84.14	5,500	462,784	207,023	May 08 08:00 PM
CARL DAMBKOWSKI	Officer	May 06 '26	Proposed Sale	83.29	22,000	1,832,380		May 06 04:25 PM
Henderson Jane	Chief Financial Officer	May 01 '26	Sale	82.04	2,000	164,080	173,371	May 04 08:00 PM
JANE HENDERSON	Officer	May 01 '26	Proposed Sale	82.89	2,000	165,780		May 01 04:45 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Apr 16 '26	Option Exercise	22.86	3,000	68,580	1,135,987	Apr 20 04:05 PM
Henderson Jane	Chief Financial Officer	Apr 16 '26	Sale	90.00	2,000	180,000	175,371	Apr 17 08:00 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Apr 08 '26	Sale	82.58	20,000	1,651,664	1,132,987	Apr 10 08:00 PM
Dambkowski Carl	Chief Medical Officer	Apr 01 '26	Option Exercise	22.86	4,125	94,298	213,898	Apr 03 08:00 PM
Dambkowski Carl	Chief Medical Officer	Apr 01 '26	Sale	84.84	5,500	466,619	208,398	Apr 03 08:00 PM
Henderson Jane	Chief Financial Officer	Apr 01 '26	Sale	85.01	2,000	170,020	177,371	Apr 03 08:00 PM
Henderson Jane	Chief Financial Officer	Mar 25 '26	Sale	85.00	2,000	170,000	179,371	Mar 27 08:00 PM
JANE HENDERSON	Officer	Mar 25 '26	Proposed Sale	73.00	6,000	438,000		Mar 25 04:24 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Mar 11 '26	Sale	74.78	20,000	1,495,605	1,152,987	Mar 13 08:00 PM
Dambkowski Carl	Chief Medical Officer	Mar 04 '26	Option Exercise	22.86	4,125	94,298	215,273	Mar 06 08:00 PM
Dambkowski Carl	Chief Medical Officer	Mar 04 '26	Sale	71.06	5,500	390,825	209,773	Mar 06 08:00 PM
Henderson Jane	Chief Financial Officer	Mar 02 '26	Sale	70.22	2,000	140,431	181,371	Mar 04 08:00 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Feb 11 '26	Sale	63.35	20,000	1,266,953	1,172,987	Feb 13 08:00 PM
HENDERSON MICHAEL THOMAS	Officer	Feb 11 '26	Proposed Sale	64.00	60,000	3,840,000		Feb 11 10:42 AM
Dambkowski Carl	Chief Medical Officer	Feb 04 '26	Option Exercise	22.86	4,125	94,298	216,648	Feb 04 08:02 PM
Dambkowski Carl	Chief Medical Officer	Feb 04 '26	Sale	65.79	5,500	361,860	211,148	Feb 04 08:02 PM
Henderson Jane	Chief Financial Officer	Feb 02 '26	Sale	65.81	2,000	131,630	183,371	Feb 04 08:01 PM
Fairmount Funds Management LLC	Director	Jan 22 '26	Sale	76.30	1,750,000	133,525,000	298,647	Jan 22 08:07 PM
Fairmount Healthcare Fund II L	Director	Jan 22 '26	Proposed Sale	76.30	1,750,000	133,525,000		Jan 22 08:03 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Jan 14 '26	Sale	81.11	20,000	1,622,159	1,192,987	Jan 16 08:00 PM
Dambkowski Carl	Chief Medical Officer	Jan 07 '26	Option Exercise	22.86	14,025	320,612	231,223	Jan 09 08:00 PM
Dambkowski Carl	Chief Medical Officer	Jan 07 '26	Sale	77.84	18,700	1,455,613	212,523	Jan 09 08:00 PM
CARL DAMBKOWSKI	Officer	Jan 07 '26	Proposed Sale	78.25	35,200	2,754,400		Jan 07 04:27 PM
Henderson Jane	Chief Financial Officer	Jan 02 '26	Sale	74.86	6,000	449,146	187,371	Jan 06 08:00 PM
Henderson Jane	Chief Financial Officer	Jan 06 '26	Sale	80.00	2,000	160,000	185,371	Jan 06 08:00 PM
JANE HENDERSON	Officer	Jan 02 '26	Proposed Sale	75.48	12,000	905,760		Jan 02 04:31 PM
Henderson Jane	Chief Financial Officer	Dec 19 '25	Sale	80.00	1,500	120,000	193,371	Dec 23 08:00 PM
JANE HENDERSON	Officer	Dec 19 '25	Proposed Sale	77.35	1,500	116,025		Dec 19 04:24 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Dec 10 '25	Sale	75.38	20,000	1,507,657	1,212,987	Dec 12 08:00 PM
Dambkowski Carl	Chief Medical Officer	Dec 04 '25	Sale	75.00	10,900	817,500	271,108	Dec 05 08:03 PM
Henderson Jane	Chief Financial Officer	Dec 04 '25	Sale	75.00	1,500	112,500	194,871	Dec 05 08:02 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Dec 04 '25	Sale	75.01	40,000	3,000,400	1,232,987	Dec 05 08:00 PM
JANE HENDERSON	Officer	Dec 04 '25	Proposed Sale	74.55	1,500	111,825		Dec 04 04:43 PM
CARL DAMBKOWSKI	Officer	Dec 04 '25	Proposed Sale	74.55	10,900	812,595		Dec 04 04:41 PM
Henderson Jane	Chief Financial Officer	Nov 25 '25	Sale	70.00	1,500	105,000	196,371	Nov 28 08:00 PM
JANE HENDERSON	Officer	Nov 25 '25	Proposed Sale	67.85	1,500	101,775		Nov 25 04:28 PM
Henderson Jane	Chief Financial Officer	Nov 14 '25	Sale	65.00	2,000	130,000	197,871	Nov 14 08:00 PM
JANE HENDERSON	Officer	Nov 14 '25	Proposed Sale	62.97	2,000	125,940		Nov 14 04:31 PM
Henderson Jane	Chief Financial Officer	Nov 11 '25	Sale	60.00	1,000	60,000	199,871	Nov 13 08:37 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Nov 13 '25	Sale	63.01	20,000	1,260,236	1,272,987	Nov 13 08:24 PM
HENDERSON MICHAEL THOMAS	Officer	Nov 13 '25	Proposed Sale	66.98	100,000	6,697,800		Nov 13 10:33 AM
JANE HENDERSON	Officer	Nov 11 '25	Proposed Sale	56.77	1,000	56,770		Nov 12 07:03 AM
Dambkowski Carl	Chief Medical Officer	Nov 05 '25	Option Exercise	22.86	8,060	184,252	292,793	Nov 07 08:00 PM
Dambkowski Carl	Chief Medical Officer	Nov 05 '25	Sale	55.07	10,785	593,903	282,008	Nov 07 08:00 PM
CARL DAMBKOWSKI	Officer	Nov 05 '25	Proposed Sale	53.90	10,785	581,312		Nov 05 04:17 PM
Dambkowski Carl	Chief Medical Officer	Oct 01 '25	Option Exercise	22.86	2,385	54,521	289,843	Oct 03 08:00 PM
Dambkowski Carl	Chief Medical Officer	Oct 01 '25	Sale	39.80	5,110	203,378	284,733	Oct 03 08:00 PM
Dambkowski Carl	Chief Medical Officer	Sep 03 '25	Sale	37.87	2,725	103,198	233,548	Sep 05 08:00 PM
Dambkowski Carl	Chief Medical Officer	Aug 06 '25	Sale	37.78	2,725	102,950	236,273	Aug 08 08:00 PM
Dambkowski Carl	Chief Medical Officer	Jul 02 '25	Option Exercise	22.86	7,365	168,364	249,088	Jul 03 08:00 PM
Dambkowski Carl	Chief Medical Officer	Jul 02 '25	Sale	45.09	10,090	454,954	238,998	Jul 03 08:00 PM
CARL DAMBKOWSKI	Officer	Jul 02 '25	Proposed Sale	44.26	22,345	988,990		Jul 02 04:22 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

APGE

Apogee Therapeutics Inc

Upgrade your Finviz experience